Posted on 09/10/2009 in Pharmaceutical Company Product News Sanofi Pasteur has announced that a single dose of its H1N1 vaccines Panenza (15 mcg dose, non-adjuvanted) or Humenza (3.8 mcg dose, adjuvanted) provokes a robust immune response.
This is according to the results of the latest trial into the products, which encompassed children of three years of age and older, as well as adults.
A single dose of Panenza or Humenza induced a robust antibody response that is considered to be protective in 93 per cent or more of adults aged between 18 and 59 years old.
The same results were recorded among 83 per cent or more of adults aged 60-plus and 94 per cent of children aged between three and 17.
Wayne Pisano, president and chief executive officer of the firm, commented: "This significant clinical data concerning Sanofi Pasteur's pandemic influenza vaccines will help build public confidence [and] will support efforts by health authorities to face the challenge posed by pandemic influenza."
Sanofi Pasteur revealed recently that it has entered into a partnership with the Alliance for Rabies Control in a bid to raise awareness of the disease.
Other news stories from 09/10/2009
Read more in the Zenopa News Archive
How this news is generated
|
